Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer

J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):27-39. doi: 10.1007/s10911-006-9010-8.

Abstract

The peptide growth factors IGF-I and IGF-II not only play a role in the development of the mammary gland but are also implicated in breast cancer. Several reagents disrupting IGF signaling have been developed and clinical trials validating IGF signaling as a target in cancer therapy are underway. This review highlights the approaches to inhibiting IGF signaling in breast cancer.

Publication types

  • Review

MeSH terms

  • Antibodies, Neoplasm / therapeutic use
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / immunology
  • Breast Neoplasms / metabolism
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Receptor, IGF Type 1 / antagonists & inhibitors*
  • Receptor, IGF Type 1 / immunology
  • Receptor, IGF Type 1 / metabolism
  • Signal Transduction / drug effects

Substances

  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Receptor, IGF Type 1